Apr. 2 at 5:34 PM
$SKYE continues to build on its focused approach to optimizing dose and exposure of nimacimab.
We recently treated the first patient in our higher-dose CBeyond Expansion Study, designed to evaluate the relationship between exposure and safety and inform Phase 2b dose selection.
Building on encouraging results from our initial CBeyond study, this step advances our understanding of how to engage peripheral CB1 targets and support a differentiated, add-on approach to GLP-1 therapies.
As our work progresses, we look forward to sharing more on how these data may help define the dose-efficacy relationship, confirm safety at higher exposure levels, and support Phase 2b planning.
Read the release: https://ir.skyebioscience.com/news-releases/detail/256/skye-bioscience-treats-first-patient-in-nimacimab-higher-dose-expansion-study-evaluating-exposure-response-to-inform-phase-2b-dose-selection-for-glp-1-combination-development
#Biotech #Obesity #ClinicalDevelopment
